【摘要】 目的 探讨孕激素受体膜成分1(progesterone receptor membrane component 1, PGRMC1)在子宫内膜癌（endometrial cancer, EC）保留生育功能治疗中的表达变化及临床意义，评估其作为疗效预测标志物的潜力。方法 采用免疫组化（二步法）检测15例EC患者治疗前肿瘤组织、治疗3～6个月肿瘤组织以及完全缓解（complete remission, CR）3个月内子宫内膜组织中的PGRMC1表达，分析其动态变化及其与雌激素受体（estrogen receptor, ER）、孕激素受体（progesterone receptor, PR）、Ki-67的相关性。并基于UALCAN和CPTAC数据库分析PGRMC1在EC中的表达特征及预后价值。结果 PGRMC1在EC组织中呈强阳性表达，达完全缓解后其表达显著下降[2.70(2.25, 2.85); 1.00(1.00, 2.10), P=0.002]，且与PR表达呈正相关（r=0.66, P=0.01）。数据库数据分析显示，PGRMC1高表达组EC患者总体生存率（OS）显著缩短，这一趋势在Ⅰ期和低级别EC亚组中保持一致（P均<0.05）。结论 PGRMC1表达水平与EC患者预后及孕激素治疗疗效密切相关，其动态下降可能作为疗效预测的潜在标志物。更多还原

【Abstract】 Objective To evaluate progesterone receptor membrane component 1(PGRMC1) as a potential biomarker for predicting fertility-sparing treatment outcomes in endometrial cancer(EC). Methods Immunohistochemistry(two-step method) was performed to analyze PGRMC1 expression patterns in EC tissues before treatment, at 3-6 months during treatment, and within 3 months after complete remission(CR). Correlations with estrogen receptor(ER), progesterone receptor(PR), and Ki-67 were assessed. UALCAN and CPTAC databases were used for validation. Results PGRMC1 showed strong positivity in EC tissues, and the expression decreased after remission [2.70(2.25, 2.85) vs 1.00(1.00, 2.10), P = 0.002]. Positive correlation with PR was observed(r = 0.66, P = 0.01). Database analysis revealed that high PGRMC1 expression predicted worse overall survival in EC patients, consistent across stage Ⅰ and low-grade subgroups(all P < 0.05). Conclusions PGRMC1 expression is closely related to EC prognosis and progesterone treatment efficacy; its dynamic decrease may be a potential predictive marker.更多还原